Observational study on chemo-radiotherapy for early-stage esophageal cancer after endoscopic dissection

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, prospective observational cohort study aims to optimize individualized chemoradiotherapy regimens for patients with high-risk early-stage esophageal cancer who have undergone endoscopic submucosal dissection. The study focuses on improving local-regional lymph node control rates while minimizing the toxicity associated with chemoradiotherapy. By analyzing patient outcomes, the study seeks to enhance treatment strategies and provide tailored approaches for better management of this condition.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1\. Esophageal cancer patients who are pathologically confirmed as pT1a-MM stage or pT1b stage after endoscopic submucosal dissection； 2. No definite contraindications for chemo-radiotherapy； 3. Informed consent has been signed； 4. Refused surgery after endoscopic submucosal dissection.

Exclusion Criteria:

* 1\. Severe heart, brain, lung disease or renal dysfunction; 2. Previous history of other malignancies; 3. Prior radiation or chemotherapy 4. Researchers consider it inappropriate to participate in this experiment

Where it's running

• The Second Affiliated Hospital of Zhejiang University School of Medicine
  Hangzhou, Zhejiang, China Recruiting
• The Second Affiliated Hospital of Zhejiang University, School of Medicine
  Hangzhou, China Not yet recruiting

Study contacts

• Study coordinator: Jing Xu, MD
• Email: jing_xu@zju.edu.cn
• Phone: 0086-0571-87783521

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Personalized Ultrafractionated Stereotactic Radiotherapy with Perioperative FLOT for GEJ and Esophageal Cancer

  This trial tests adding a personalized, ultra-fractionated radiotherapy boost (PULSAR) to standard perioperative FLOT chemotherapy for patients with esophageal or gastroesophageal junction cancer to see if it can be used safely.

  Recruiting Phase 1 University of Texas Southwestern Medical Center · Dallas, Texas · NCT07700420

• Preventing nausea and vomiting during multi-cycle chemo and immunotherapy in esophageal and lung cancer

  This study tests a combination antiemetic with dexamethasone to see if it lowers nausea and vomiting in adults with esophageal or lung cancer receiving several cycles of chemo plus immunotherapy.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07617246

• Ivonescimab plus FOLFOX for advanced HER2-negative stomach and gastroesophageal junction adenocarcinoma

  This study tests whether adding ivonescimab to standard FOLFOX chemotherapy helps people with advanced, HER2-negative stomach or gastroesophageal junction adenocarcinoma as first-line treatment.

  Recruiting at 2 sites Phase 2 Massachusetts General Hospital · Santa Monica, California and 1 other locations · NCT07070466

• AI prediction of response to pre-surgery chemoimmunotherapy for esophageal cancer

  This project tests whether combining clinical records, CT scans, pathology, and lab results with deep learning can predict which patients with locally advanced esophageal cancer will respond to neoadjuvant chemoimmunotherapy before surgery.

  Recruiting Central South University · Changsha, Hunan · NCT07063901

• 18F-G1 PET/CT to see early immunotherapy response in solid tumors and blood cancers

  We are testing if the 18F-G1 PET/CT scan can help tell early on whether people with solid tumors or blood cancers will respond to immunotherapy.

  Recruiting Peking University First Hospital · Beijing · NCT07039474

• Combining afatinib and palbociclib for previously treated advanced esophageal squamous cell carcinoma

  This trial tests whether taking afatinib together with palbociclib helps control tumor growth in people with recurrent or metastatic esophageal squamous cell carcinoma who have already received prior treatments.

  Recruiting Phase 1/2 West China Hospital · Chengdu, Sichuan · NCT06753747

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.